NEW YORK (360Dx) – San Diego-based TearLab announced yesterday that its next-generation, multiplex diagnostics platform for human tear samples has received CE marking as an in vitro diagnostic medical device.

The CE mark also covers an assay for response to dry eye disease therapy, which measures both osmolarity, a measure of solute concentration, and an inflammation biomarker.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.